Cargando…

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. CCL22 was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. Recently, we showed that CCL22-specific T cells generated from cancer pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lecoq, Inés, Kopp, Katharina L., Chapellier, Marion, Mantas, Panagiotis, Martinenaite, Evelina, Perez-Penco, Maria, Rønn Olsen, Lars, Zocca, Mai-Britt, Wakatsuki Pedersen, Ayako, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427044/ https://www.ncbi.nlm.nih.gov/pubmed/36052217 http://dx.doi.org/10.1080/2162402X.2022.2115655

Ejemplares similares

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

Tumor microenvironment antigens
por: Andersen, Mads Hald
Publicado: (2022)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2021)

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
por: Andersen, Mads Hald
Publicado: (2012)

Keeping each other in check: A reciprocal relationship between cytokines and miRNA
por: Andersen, Mads Hald
Publicado: (2013)

FOXP3-specific immunity
por: Andersen, Mads Hald
Publicado: (2013)

T-cell dependent immunoselection
por: Andersen, Mads Hald
Publicado: (2012)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

The targeting of tumor-associated macrophages by vaccination
por: Andersen, Mads Hald
Publicado: (2019)

Novel immune modulatory vaccines targeting TGFβ
por: Andersen, Mads Hald
Publicado: (2023)

High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma
por: Li, Lei, et al.
Publicado: (2018)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
por: thor Straten, Per, et al.
Publicado: (2010)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma
por: Barbai, Tamás, et al.
Publicado: (2015)

Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
por: Kadomoto, Suguru, et al.
Publicado: (2021)

STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes
por: Johansen, Claus, et al.
Publicado: (2017)

EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
por: Hippe, Andreas, et al.
Publicado: (2020)

BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche
por: Chapellier, Marion, et al.
Publicado: (2015)

CCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma
por: Tong, Junyu, et al.
Publicado: (2022)

Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma
por: Kawano, Masanori, et al.
Publicado: (2021)

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021)

Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
por: Hippe, Andreas, et al.
Publicado: (2021)

Identification of the Crucial Role of CCL22 in F. nucleatum-Related Colorectal Tumorigenesis that Correlates With Tumor Microenvironment and Immune Checkpoint Therapy
por: Wang, Hufei, et al.
Publicado: (2022)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity
por: Scheu, Stefanie, et al.
Publicado: (2017)

Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment
por: Chen, Bowen, et al.
Publicado: (2020)

CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment
por: Jin, Jiakang, et al.
Publicado: (2021)

CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction
por: Hueso, Luisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_botg126rlbrhb4t53fhhpm8ikh